Abstract. The aim of the present study was to assess the expression of sirtuin (Sirt)1 in tendon stem cells (TSCs) and to elucidate its association with osteogenic and adipogenic differentiation of TSCs. Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analyses were performed to detect Sirt1 mRNA and protein levels in TSCs, respectively. TSCs were positive for Sirt1 expression, which was elevated by Sirt1 activator SRT1720 in a time-and concentration-dependent manner, and decreased by Sirt1 inhibitor EX527. TSCs were treated with SRT1720 and EX527 for various time periods and resulting changes in osteogenic and adipogenic protein markers were analyzed using alizarin red and oil red O staining. According to RT-qPCR and western blot analyses, the associated factors β-catenin, Runt-related transcription factor 2 (Runx2) and bone morphogenetic protein 2 were elevated following increases of Sirt1 levels, while CCAAT/enhancer binding protein (CEBP)α and peroxisome proliferator-activated receptor (PPAR)γ were decreased. These results suggested that osteogenic differentiation capacity was enhanced, while adipogenic differentiation capacity declined. Further mechanistic study revealed that phosphoinositide-3 kinase (PI3K) and AKT were decreased following activation of Sirt1. In conclusion, the present study suggested that Sirt1 promotes the osteogenic differentiation of TSCs through upregulating β-catenin and Runx2 and inhibits the adipogenic differentiation of TSCs through the PI3K/AKT pathway with downregulation of CEBPα and PPARγ.
Introduction
Tendinopathy is a strain-induced chronic disease whose causes remain to be elucidated. The frequency of cases of tendinopathy is increasing, and it currently accounts for ~50% of all sports injuries (1) . As conservative treatments are limited, they are unsuccessful in 24-45.5% of patients, leading to refractory tendinopathy (2) . Therefore, an enhanced understanding of the pathogenesis of tendinopathy at the cellular and molecular level is required to develop novel and more effective treatment strategies.
Tendon stem cells (TSCs) are a type of mesenchymal stem cells derived from the paratenon of the tendon. Zhang and Wang (3) indicated that TSCs have a higher potential for cell proliferation and collagen synthesis as compared with that of mature tendon cells. Under certain conditions, TSCs can be differentiated into mature tendon cells with an enhanced secretion of extracellular matrix to effectively repair tendon injury (3) . However, the underlying mechanisms of TSC differentiation have remained elusive. TSCs are pluripotent and thus capable of differentiating into adipocytes, chondrocytes and osteoblasts (4) (5) (6) (7) (8) . Their multi-directional differentiation potential has an important role in the process of tendon repair. Insight into the regulation of TSC differentiation may provide novel strategies for the treatment of tendinopathy, as these cells may be utilized for tendon injury repair.
Si r t1 is a nicotinam ide adenine dinucleotide (NAD + )-dependent histone deacetylase, which has an important role in energy metabolism and cell differentiation (9) . A study has shown that Sirt1 can regulate osteogenic differentiation by self-deacetylation in mesenchymal stem cells (10) . Resveratrol, an activator of Sirt1, can decrease the number of adipocytes and increase the expression of osteoblast markers (11) . Inhibition of Sirt1 can increase the number of adipocytes and lipoblast markers and reduce the expression of osteoblast markers. Thus, the activation of Sirt1 can inhibit adipogenic differentiation and promote osteogenic differentiation (11) . However, the expression status of Sirt1 in TSCs and the underlying mechanisms of its possible regulation of osteogenic and adipogenic differentiation in TSCs have remained elusive.
Using reverse-transcription quantitative polymerase chain reaction (RT-qPCR) and western blot analyses, the present
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study assessed the gene and protein expression of Sirt1 in TSCs following treatment with a Sirt1 activator or inhibitor for various time periods. In addition, the present study assessed the resulting differentiation into osteoblasts and lipoblasts and elucidated the molecular mechanism of Sirt1-mediated regulation of osteogenic and adipogenic differentiation of TSCs. The present study provided insight into the molecular mechanisms of Sirt1-induced TSC differentiation, which may be harnessed for the development of novel and effective treatments for tendon injury. RT-qPCR. RNA was extracted with TRIzol reagent (Invitrogen; Thermo Fisher Scientific Inc., Waltham, MA, USA; 1 ml per 1x10 7 cells) and cDNA was synthesized using the RNA reverse transcription kit (cat no. DRR047A; Takara, Dalian, China) according to the manufacturer's instructions. The sequences of the Sirt1 gene primers were 5'-CCA GAT CCT CAA GCC ATG T-3' for the forward primer and 5'-TTG GAT TCC TGC AAC CTG-3' for the reverse primer. The sequences of the Runx2 gene primers were 5'-TGA TGA CAC TGC CAC CTC TGA CTT-3' for the forward primer and 5'-TGG ATA GTG CAT TCG TGG GTT GGA-3' for the reverse primer. The sequences of the PPARγ gene primers were 5'-ATG ACC ACT CCC ATT CCT TT-3' for the forward primer and 5'-TGA TCG CAC TTT GGT ATT CTT-3' for the reverse primer. The sequences of the GAPDH primers were 5'-ATG GAA ATC CCA TCA CCA TCT T-3' for the forward primer and 5'-CGC CCC ACT TGA TTT TGG-3' for the reverse primer. The primers were obtained from Sangon Biotech Co. Ltd. (Shanghai, China). A total of 5 µl cDNA from each sample was obtained and PCR was performed in 25 µl reactions containing Platinum SYBR Green qPCR SuperMix-UDG and appropriate primers in the ABI StepOne Plus system from Applied Biosystems (Foster City, CA, USA). Cycling parameters were as follows: Denaturation, 95˚C for 10 min followed by 45 cycles consisting of denaturation at 95˚C for 20 sec, annealing at 60˚C for 25 sec, extension at 72˚C for 30 sec, and a controlled increase to 95˚C with a heating rate of 0.1˚C/sec. Target gene expression was normalized to that of GAPDH. Data were analyzed using the comparative threshold cycle (Cq) method. The melting curves were analyzed after amplification. PCR reactions of each sample were performed in triplicate. Data were analyzed using the comparative 2 -ΔΔCq method.
Materials and methods

Isolation
Protein extraction and western blot analysis. Cells were scraped and homogenized in lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) containing a mixture of proteinase inhibitors (Thermo Fisher Scientific Inc.). Protein concentrations were measured using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). Protein samples (40 µg/lane) were resolved by 10% SDS-PAGE and transferred onto polyvinylidene difluoride membranes. After blocking with 0.1% Tris-buffered saline containing Tween 20 (Beyotime Institute of Biotechnology) and 5% non-fat milk for 1 h at 20˚C, membranes were incubated at 4˚C for 1 h sequentially with primary and secondary antibodies. The following primary antibodies purchased from Abcam (Cambridge MA, USA) were used: Anti-Sirt1 (monoclonal mouse IgG; 1:1,000 dilution; cat. no. ab50517), anti-β-catenin (monoclonal mouse IgG; 1:800 dilution; cat. no. ab22656), anti-Runt-related transcription factor 2 (Runx2; monoclonal mouse IgG; 1:1,000 dilution; cat. no. ab115899), anti-CCAAT/enhancer binding protein (CEBP)α (monoclonal mouse IgG; 1:1,000 dilution; cat. no. ab128482) and anti-peroxisome proliferator-activated receptor (PPAR)γ (monoclonal mouse IgG; 1:1200 dilution; cat. no. ab138004), anti-PI3K (monoclonal mouse; 1:1,000 dilution; cat. no. ab86714), anti-AKT (monoclonal rabbit IgG; 1:1,500 dilution; cat. no. ab32505), anti-BMP2 (monoclonal rabbit IgG; 1:1,000 dilution; cat. no. ab183729). Subsequently, the membranes were incubated at room temperature for 2 h with peroxidase-labeled anti-mouse IgG antibody (1:1,000 dilution; cat. no. A0216; Beyotime Institute of Biotechnology) or anti-rabbit IgG antibody (1:1,000 dilution; cat. no. A0208; Beyotime Institute of Biotechnology). Proteins were visualized using an enhanced chemiluminescence (ECL) reagent (Amersham ECL Prime detection; GE Healthcare, Little Chalfont, UK). Experiments were performed in triplicate.
Alizarin red staining. Cells were fixed in 70% ethanol for 1 h and stained with 2% alizarin red solution (Beyotime Institute of Biotechnology; pH 4.1-4.5) for 30 min at 20˚C. The stained cells were examined under an inverted microscope (ix71; Olympus Corporation, Tokyo, Japan). Photomicrographs were obtained using a charge-coupled device camera.
Oil Red O staining. Adipocytes were identified by staining with Oil Red O (Sigma-Aldrich) as described previously (15) . The area of the cells stained with Oil Red O was measured using ImagePro Plus 6.0 software (Media Cybernetics, Rockville, MD, USA).
Statistical analysis. SPSS version 17.0 (SPSS, Inc, Chicago, IL, USA) software was used for statistical analysis. Values are expressed as the mean + standard deviation. Multiple comparisons were made using one-way analysis of variance followed by Fisher's exact test. P<0.05 was considered to indicate a statistically significant difference between values.
Results
Sirt1 is expressed in TSCs and drives osteogenic differentiation.
In order to investigate the association between Sirt1 and the osteogenic and adipogenic differentiation of TSCs, the present study first detected Sirt1 mRNA and protein expression in TSCs. As shown in Fig. 1 , TSCs expressed Sirt1, which was further enhanced by Sirt1 activator SRT1720 in a concentration-and time-dependent manner. Conversely, Sirt1 expression decreased in the presence of Sirt1 inhibitor EX527 in a time-dependent manner (P<0.05). Next, the present study evaluated the expression of adipogenic and osteogenic differentiation markers in TSCs on days 3, 7, 10 and 14 of treatment with Sirt1 activator and inhibitor. The expression of BMP2 and Runx2 appeared to be positively correlated with Sirt1 expression, which indicated that Sirt1 increases the capacity of TSCs for osteogenic differentiation (Fig. 2) . Peak values of BMP2 and Runx2 expression were observed on day 10, followed by a marked decrease in osteogenic differentiation capacity of TSCs during prolonged treatment with Sirt1 activator. However, the adipogenic differentiation capacity of TSCs was gradually reduced (P<0.05).
Sirt1 enhances osteogenic and decreases adipogenic differentiation of tendon stem cells.
Alizarin red staining was used to assess the osteogenic differentiation and oil red O staining was used to detect the adipogenic differentiation of tendon stem cells after treatment with SRT1720 (0.4 µM) (Fig. 3) . In accordance with the effects of Sirt1 on the expression of differentiation markers (Fig. 2) , staining showed that the capacity 
Sirt1 drives osteogenic differentiation of TSCs via upregulating β-catenin and Runx2 and represses adipogenic differentiation of TSCs through downregulating CEBPα and PPARγ and the PI3K/AKT pathway.
The present study showed that increases in Sirt1 expression in TSCs enhanced β-catenin and Runx2 expression, while the expression of PI3K, AKT, CEBPα and PPARγ was decreased (Fig. 4) . Furthermore, treatment with Sirt1 inhibitor reduced not only Sirt1 expression but also β-catenin and Runx2 expression, while enhancing the 
Discussion
Sirt1 is an NAD-dependent deacetylase which is important in numerous biological processes, including cell cycle regulation, cell differentiation, cell survival and apoptosis. Sirt1 regulates osteogenic differentiation of mesenchymal stem cells by deacetylating H3K9 in the promoter sequence of the Sost gene, which encodes sclerostin (10) . The present study confirmed that Sirt1 is expressed in TSCs and revealed that it enhances their osteogenic differentiation capacity in a time-dependent manner. Furthermore, the gene and protein levels of osteogenesis marker BMP2, were elevated by Sirt1 in a time-dependent manner. Peak values of BMP2 expression were observed on day 10 followed of treatment with Sirt1 activator. Conversely, the osteogenic differentiation capacity of TSCs was decreased after treatment with Sirt1 inhibitor. By contrast, treatment with Sirt1 activator reduced the adipogenic capacity of TSCs, while it was increased by the Sirt1 inhibitor.
Recently, Simic et al (16) showed that Sirt1 deacetylates Runx2 and β-catenin to regulate the differentiation of mesenchymal stem cells. Sirt1 activated by resveratrol was reported to promote osteogenic differentiation of mesenchymal stem cells by increasing Runx2 expression, increasing its combination with PPARγ and inhibiting the activity of PPARγ through its cofactor nuclear receptor co-repressor 1 (NCoR1) (14) . PPARγ has an important role in the balance of adipogenic and osteogenic differentiation of mesenchymal stem cells (15) . Overexpressed Sirt1 can be anchored to NCoR1 and -2, the inhibitory co-factors of PPARγ, which in turn suppresses the expression of PPARγ and C/EBPα and further inhibits the cytopoiesis of adipocytes (i.e. it reduces the transformation of pre-adipocytes into adipocytes) (14) . Furthermore, Sirt1 can inhibit the transcriptional activity of AKT2 and interact with AKT2 and CEBPα (16) . Silencing of AKT2 and/or Sirt1 was shown to affect pre-adipogenesis through the PI3K/AKT pathway, which exhibits a synergy with the CEBPα pathway (16) . The present study explored whether Sirt1 regulates the differentiation of TSCs in a similar manner to that of mesenchymal stem cells.
In the present study, it was revealed that increased Sirt1 expression enhanced β-catenin and Runx2 expression in TSCs and reduced the expression of PI3K, AKT, CEBPα and PPARγ, while treatment with Sirt1 inhibitor had the opposite effect. It is therefore concluded that Sirt1 promotes osteogenic differentiation of TSCs through upregulation of β-catenin and Runx2, while inhibiting adipogenic differentiation of TSCs via inhibiting the PI3K/AKT pathway as well as the expression of CEBPα and PPARγ.
In conclusion, to the best of our knowledge, the present study was the first to report that Sirt1 is endogenously expressed in TSCs. Sirt1 was demonstrated to time-dependently promote the osteogenic differentiation of TSCs through upregulating β-catenin and Runx2 and to inhibit the adipogenic differentiation of TSCs through inhibiting the PI3K/AKT pathway with downregulation of CEBPα and PPARγ. During the process of tendon injury repair, TSCs favor differentiation into cartilage and bone, while the accumulation of adipose tissue is not conducive to the recovery from tendinopathy. Therefore, by targeting Sirt1, it may be possible to regulate osteogenic differentiation of TSCs as well as adipose accumulation in injured tendons. Upregulation of Sirt1 may be an efficient strategy for the treatment of refractory tendinopathy using TSCs. This approach may represent a breakthrough leading to the development of novel clinical techniques with the potential to fundamentally improve the treatment of sports injuries.
